Futibatinib
Sign in to save this workspacePrimary targets: FGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.48
Gini
0.718
CATDS
0.032
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Futibatinib. Strongest target: FGFR2 at 99.3% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR2 | 99.3% | 0.7% |
| 2 | FGFR3 | 99.0% | 1.0% |
| 3 | FGFR1 | 99.0% | 1.0% |
| 4 | FGFR4 | 97.9% | 2.1% |
| 5 | RET | 97.7% | 2.3% |
| 6 | BMX_ETK | 95.2% | 4.8% |
| 7 | FGR | 81.5% | 18.5% |
| 8 | JAK2 | 81.4% | 18.6% |
| 9 | TRKC | 78.4% | 21.6% |
| 10 | YES_YES1 | 70.3% | 29.7% |
| 11 | TRKB | 65.5% | 34.5% |
| 12 | JAK1 | 64.4% | 35.6% |
| 13 | MKK7 | 60.4% | 39.6% |
| 14 | ROS_ROS1 | 58.1% | 41.9% |
| 15 | DDR1 | 56.4% | 43.6% |
| 16 | CK1EPSILON | 54.8% | 45.2% |
| 17 | ZAP70 | 46.1% | 53.9% |
| 18 | BLK | 42.6% | 57.4% |
| 19 | FLT4_VEGFR3 | 41.8% | 58.2% |
| 20 | FLT3 | 32.8% | 67.2% |
Selectivity landscape
Where Futibatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Futibatinib.
Atlas insights for Futibatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target5%
Off-target95%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 999.27 | |
| ALLOGRAFT_REJECTION | 3421.68 | |
| ANDROGEN_RESPONSE | 761.52 | |
| ANGIOGENESIS | 479.92 | |
| APICAL_JUNCTION | 3408.81 | |
| APICAL_SURFACE | 363.64 | |
| APOPTOSIS | 2175.47 | |
| BILE_ACID_METABOLISM | 335.92 | |
| CHOLESTEROL_HOMEOSTASIS | 428.31 | |
| COAGULATION | 197.40 | |
| COMPLEMENT | 1655.54 | |
| DNA_REPAIR | 671.77 | |
| E2F_TARGETS | 1538.86 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 503.49 | |
| ESTROGEN_RESPONSE_EARLY | 987.02 | |
| ESTROGEN_RESPONSE_LATE | 1025.71 | |
| FATTY_ACID_METABOLISM | 665.89 | |
| G2M_CHECKPOINT | 1665.02 | |
| GLYCOLYSIS | 1144.85 | |
| HEDGEHOG_SIGNALING | 127.06 | |
| HEME_METABOLISM | 701.82 | |
| HYPOXIA | 1518.26 | |
| IL2_STAT5_SIGNALING | 1132.66 | |
| IL6_JAK_STAT3_SIGNALING | 3258.07 | |
| INFLAMMATORY_RESPONSE | 1635.13 | |
| INTERFERON_ALPHA_RESPONSE | 323.95 | |
| INTERFERON_GAMMA_RESPONSE | 2891.01 | |
| KRAS_SIGNALING_DN | 247.89 | |
| KRAS_SIGNALING_UP | 985.66 | |
| MITOTIC_SPINDLE | 1845.78 | |
| MTORC1_SIGNALING | 1332.43 | |
| MYC_TARGETS_V1 | 979.47 | |
| MYC_TARGETS_V2 | 167.46 | |
| MYOGENESIS | 960.01 | |
| NOTCH_SIGNALING | 72.90 | |
| OXIDATIVE_PHOSPHORYLATION | 1038.69 | |
| P53_PATHWAY | 973.33 | |
| PANCREAS_BETA_CELLS | 84.10 | |
| PEROXISOME | 324.67 | |
| PI3K_AKT_MTOR_SIGNALING | 4609.60 | |
| PROTEIN_SECRETION | 988.90 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 79.25 | |
| SPERMATOGENESIS | 600.26 | |
| TGF_BETA_SIGNALING | 687.70 | |
| TNFA_SIGNALING_VIA_NFKB | 1561.11 | |
| UNFOLDED_PROTEIN_RESPONSE | 522.11 | |
| UV_RESPONSE_DN | 1561.60 | |
| UV_RESPONSE_UP | 1162.35 | |
| WNT_BETA_CATENIN_SIGNALING | 673.85 | |
| XENOBIOTIC_METABOLISM | 775.86 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.809 |
| SRR10899984 | — | 0.803 |
| SRR23303752 | — | 0.802 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.793 |
| aMVAC.P_005_TURBT_S223 | — | 0.787 |
Annotations
Sign in to read and post annotations.
Loading…